• Executive Board and Supervisory Board approved by a qualified majority
  • Shareholders vote for change of company name to BRAIN Biotech AG
  • Shareholder majority approves capital anticipatory resolutions

At today's Annual General Meeting of B.R.A.I.N. Biotechnology Research and Information Network AG (BRAIN AG), the discharge of the Executive Board and Supervisory Board was approved by a large majority. All of the Annual General Meeting resolutions were passed by the shareholders, including the application for conditional and authorized capital as well as the change of the company name to BRAIN Biotech AG.

Since its foundation 28 years ago, BRAIN has evolved from a research-driven and network-oriented biotech startup into a production-oriented, integrated company with a strong scientific foundation. In the future, this development will also be reflected in the name.

Chief Executive Officer Adriaan Moelker summarizes the positive developments as: 'We focused our development pipeline on seven promising R&D programs; together with our partner Roquette we have transferred our protein sweetener Brazzein to the commercialization phase; we purchased the outstanding minority stake of WeissBioTech; and we have again invested in the promising enzymatic wound-cleaning program as part of our SolasCure shareholding. Last but not least, our effective crisis management of the Covid 19 pandemic and forward-looking actions with regard to the Brexit also contributed to a successful fiscal year.'

Chief Financial Officer Lukas Linnig had presented the financial figures for the past fiscal year and said: 'During the Corona pandemic, BRAIN's overall core business has proven to be sustainable. We are now working continuously to further develop the structure of the BRAIN Group and are investing significantly in our own research and development as well as in our future products.'

The shareholders' meeting elected three candidates to the Supervisory Board, including Professor Dr.-Ing. Wiltrud Treffenfeldt and Stephen Catling, both of whom had been members of the Supervisory Board on the basis of a court appointment since October 14, 2020 until this shareholders' meeting. Dr. Anna Carina Eichhorn, a member of the Supervisory Board since 2017 and currently Deputy Chairwoman, was re-elected to the Board by the shareholders' meeting.

The Chairman of the Supervisory Board, Dr. Georg Kellinghusen, who chaired the Annual General Meeting, was very satisfied with the developments in the past financial year: 'Following some significant management changes, BRAIN has now restored management continuity. The company has made good progress in the past year in developing itself in regards to business, organization and strategy. The company is well positioned to achieve its medium-term goals.'

At the time of voting on the agenda items, between 11,367,594 and 13,505,974 of the capital stock divided into 19,861,360 registered shares were represented. The participation rate in voting, measured against the capital stock, was hence between 57.23% and 68.00%.

The detailed voting results as well as the presentation of the Management Board and all other documents relating to the Annual General Meeting are available on the BRAIN AG website at https://www.brain-biotech.com/investors/annual-general-meetings/agm-fy-2019-20

Attachments

  • Original document
  • Permalink

Disclaimer

BRAIN - Biotechnology Research And Information Network AG published this content on 10 March 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 27 March 2021 09:21:04 UTC.